Ferring acquires ex-U.S. assets and rights for Vitaros® (alprostadil cream), Apricus’ on-demand topical cream for erectile dysfunction
Saint-Prex, Switzerland – 09 March 2017 –
Ferring Pharmaceuticals today announced an agreement with Apricus Biosciences, Inc. (Nasdaq:APRI), granting Ferring global assets and rights, excluding the U.S., related to Apricus’ Vitaros® (alprostadil cream). Vitaros is an on-demand topical cream indicated for the treatment of patients with erectile dysfunction.
Ferring is Apricus’ existing commercialisation partner for Vitaros in Latin America and parts of Europe and Asia. Following an agreed handover period, Ferring will be responsible for managing all Vitaros-related activities outside of the U.S. with existing Vitaros commercialisation partners. Apricus will retain its Vitaros rights in the U.S.
“Urology is a key therapeutic area for Ferring,” said Michel Pettigrew, President of the Executive Board and COO, Ferring Pharmaceuticals. “This agreement strengthens our existing portfolio and reinforces Ferring’s commitment to improving the quality of life of patients with a broad range of urological conditions.”
– ENDS –
About Ferring Pharmaceuticals
Headquartered in Saint-Prex, Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.
For further information on Ferring or its products, visit www.ferring.com.
*Vitaros® is a registered trademark of NexMed International Limited, and will be assigned to Ferring B.V. worldwide, excluding the United States. Such trademark is registered in certain countries throughout the world and pending registration in the United States.